– Influential voice in medical cannabis policy in Europe
– A leading world authority in neurological rehabilitation
TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian“) (TSXV:SCYB) (Frankfurt:9SB) (OTCQB:SCCYF) is pleased to announce that Professor Michael Barnes will be joining the Company as Chief Medical Officer.
Professor Barnes MD FRCP is considered to be a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe. Professor Barnes appointment as Scythian’s Chief Medical Officer aligns with Scythian’s goal of providing patients access to alternative treatment with pharmaceutical grade medical cannabis.
“Professor Barnes is a strong advocate of expanding medical cannabis use and is a respected global leader in the field of neuroscience,” said Vic Neufeld, a member of Scythian’s Board of Directors. “His powerful voice brings added credibility to Scythian’s mission to make safe and precisely dosed medical cannabis accessible to a growing number of patients in need.”
In line with Scythian’s ongoing efforts to develop cannabis-based therapies, Professor Barnes played a critical role in the development of Sativex®, a proprietary product developed by GW Pharmaceuticals. Sativex® is an oromucosal spray of formulated sativa plant extract for the treatment of spasticity due to multiple sclerosis.
Professor Barnes is the co-author of a report entitled Cannabis: The Evidence for Medical Use (the “Barnes Report“), an expert independent opinion commissioned by the United Kingdom’s All-Party Parliamentary Group on Drug Policy Reform. The Barnes Report concluded, based on a literary review of more than 20,000 research papers concerning the use of drugs containing cannabinoids, that cannabis-based medication helped with a wide range of conditions. The Barnes Report has influenced law makers in Ireland, Jersey and Guernsey. Ireland is considering legalizing the use of cannabis for treating specific medical conditions, due, in part, to …